Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Birchview Capital, LP

Q4 2023 · 13F-HR/A

Birchview Capital, LPholdings as filed

Filed 2025-06-30 · accession 0001618205-25-000004

$127.8M
Reported value
58
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
110122108BMYBRISTOL-MYERS SQUIBB CO$36.0M28.2%702,298CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$10.2M7.96%77,240CommonSOLE
09075X108BIODESIX INC COM RST$9.8M7.66%5,348,273CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$7.5M5.89%240,400CommonSOLE
G72800108PRTAPROTHENA CORP PLC$6.2M4.82%169,574CommonSOLE
45253H101IMGNEURIMMUNOGEN INC$5.6M4.36%188,000CommonSOLE
74838J101QUIDELORTHO CORP$4.8M3.76%65,203CommonSOLE
69047Q102OVVOVINTIV INC$3.7M2.89%84,200CommonSOLE
05479K106ELUTELUTIA INC$3.6M2.80%1,655,184CommonSOLE
71944F106PHRPHREESIA INC$2.7M2.08%114,700CommonSOLE
91307C102UTHRUNITED THERAPEUTICS CORP$2.4M1.89%11,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$2.1M1.63%25,000CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$2.1M1.62%320,930CommonSOLE
82710M100SILKUSDSILK ROAD MEDICAL INC$1.9M1.52%158,094CommonSOLE
45720L107INBXUSDINHIBRX INC$1.8M1.44%48,448CommonSOLE
574795100MASIMASIMO CORP$1.8M1.40%15,280CommonSOLE
415858109HROWHARROW HEALTH INC$1.7M1.31%150,000CommonSOLE
88025U109TXG10X GENOMICS INC$1.7M1.31%30,000CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$1.6M1.27%50,000CommonSOLE
G01767105ALKSALKERMES PLC$1.4M1.09%50,000CommonSOLE
294600101ETRNUSDEQUITRANS MIDSTREAM CORPORATIO$1.4M1.06%133,050CommonSOLE
02081G201ATECALPHATEC HOLDINGS INC$1.3M1.04%88,000CommonSOLE
05463X106AXGNAXOGEN INC$1.2M0.92%173,000CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$1.1M0.86%210,000CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$1.1M0.86%48,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$1.1M0.86%122,000CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$1.1M0.84%18,000CommonSOLE
00430H102ACCELERATE DIAGNOSTICS INC$882,9360.69%225,239CommonSOLE
723787107PXDEURPIONEER NATURAL RESOURCES CO$854,5440.67%3,800CommonSOLE
256086109DCGODOCGO INC$838,5000.66%150,000CommonSOLE
74340E103PGNYPROGYNY INC$817,9600.64%22,000CommonSOLE
04335A105ARVNARVINAS INC$617,4000.48%15,000CommonSOLE
G5269C101KINIKSA PHARMACEUTICALS LTD$526,2000.41%30,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$490,0000.38%40,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$460,6000.36%10,000CommonSOLE
09609G100BLUEBIRD BIO INC$443,2560.35%321,200CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$406,4050.32%469,832CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$397,3200.31%28,000CommonSOLE
40637H109HALOHALOZYME THERAPEUTICS INC$369,6000.29%10,000CommonSOLE
19249H103CHRSCOHERUS BIOSCIENCES INC$366,3000.29%110,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$365,0000.29%10,000CommonSOLE
G11196105BIOHAVEN PHARMACEUTICAL HOLDING CO LTD$315,2220.25%7,365CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$278,3200.22%7,000CommonSOLE
98401F105XNCRXENCOR INC$261,1290.20%12,300CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$255,9120.20%25,114CommonSOLE
3621LQ109GTHXEURG1 THERAPEUTICS INC$244,0000.19%80,000CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$242,4000.19%16,000CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$241,0750.19%2,500CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$240,6000.19%20,000CommonSOLE
12674W109CABACABALETTA BIO INC$227,0000.18%10,000CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$215,8000.17%10,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$202,0000.16%40,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$126,0860.10%138,176CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$119,8000.09%20,000CommonSOLE
901384107TSVT*2SEVENTY BIO INC$84,6870.07%19,833CommonSOLE
N44821101IFRXINFLARX NV$81,5000.06%50,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$71,1360.06%28,800CommonSOLE
98585K102YIELD10 BIOSCIENCE INC$4,4870.00%18,750CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.